PROBLEM TO BE SOLVED: To provide a stable liquid formulation of etanercept (Etanercept, recombinant p75 sTNFR:Fc fusion protein) that inhibits a binding with a receptor of a TNF-α cell surface.SOLUTION: A liquid preparation contains one or more stabilizers selected from methionine, lysine, histidine, and pharmaceutically acceptable salts thereof in a sufficient amount to reduce by-product formation of etanercept during storage.EFFECT: The liquid formulation effectively prevents the production of etanercept by-products and can stably maintain pharmaceutical efficacies thereof for a long period of time. Therefore, the need of reconstitution at the time of administration to a patient is reduced, the formulation in an aseptic state can be supplied to patients, and patient safety is ensured. Thus, the formulation can be effectively applied to therapeutic fields involved in pharmacological efficacy to inhibit the immune response associated with TNF-α of etanercept from now on.SELECTED DRAWING: None【課題】ＴＮＦ－αの細胞表面のレセプターとの結合を阻外する、エタネルセプト(Etanercept, recombinant p75 sTNFR:Fc融合タンパク質)の安定な液状製剤の提供。【解決手段】保管中にエタネルセプトの副産物の形成を減少させるのに十分な量のメチオニン、リシン、ヒスチジン及びこれらの薬学的に許容可能な塩から選択される一つ以上の安定化剤を含む液状製剤。【効果】前記液状製剤は、エタネルセプトの副産物の生成を効果的に防止し、エタネルセプトの薬理効能を長期間安定して保存ができ、そのため、患者への投与時に再構成する必要性が低減し、無菌状態で患者に供給ができ、患者の安全を確保できる。したがって、今後、エタネルセプトのＴＮＦ－αに係る免疫反応を抑制する薬理効能に係わる治療分野に効果的に応用できる。【選択図】なし
